Question

Arrange the following keywords into a concept map: CML, Bcr–Abl, imatinib,tyrosine kinase, dasatinib, reciprocal chromosomal translocation, fusion pro- tein, granulocyte, erythrocyte, hematopoetic stem cell, splenomegaly.

Please provide the concept map with explanation. Thanks

Answer 1

The concept map is shown in figure.The concept map is explained here.Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a form of leukemia characterized by the increased and unregulated growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood. Though no obvious causes are known,CML is linked to a genetic abnormality called reciprocal chromosomal translocation. In hematopoietic stem cells, parts of chromosomes(9 th and 22^nd) switch places. This results in a fused gene BCR-ABL encoding a fusion protein that functions like a tyrosine kinase. This fusion protein is continuously active. It activates cell cycle pathways speeding up cell division and inhibits DNA repair, causing genomic stability. Symptoms often appear in later stages which include drastic increase in count of granulocytes, splenomegaly and decrease in count of erythrocytes. Treatment methods target tyrosine kinase function of the BCR-ABL fusion protein. . Initially imanitib(tyrosine kinase inhibitor) was found to inhibit progression of CML in majority of patients. Dasatinib, another tyrosine kinase inhibitor drug is administered to patients who are either resistant to Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a form of leukemia characterized by the increased and unregulated growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood. Though no obvious causes are known,CML is linked to a genetic abnormality called reciprocal chromosomal translocation. In hematopoietic stem cells, parts of chromosomes(9 th and 22^nd) switch places. This results in a fused gene BCR-ABL encoding a fusion protein that functions like a tyrosine kinase. This fusion protein is continuously active. It activates cell cycle pathways speeding up cell division and inhibits DNA repair, causing genomic stability. Symptoms often appear in later stages which include drastic increase in count of granulocytes, splenomegaly and decrease in count of erythrocytes was Treatment methods target tyrosine kinase function of the BCR-ABL fusion protein. . Initially imanitib(tyrosine kinase inhibitor) was found to inhibit progression of CL in majority of patients. Dasatinib, another tyrosine kinase inhibitor drug is administered to patients who are either resistant to or intolerant of imatinib. .